Nuwellis (NASDAQ:NUWE – Get Free Report) and Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Nuwellis and Nihon Kohden, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuwellis | 1 | 0 | 1 | 0 | 2.00 |
| Nihon Kohden | 0 | 0 | 0 | 1 | 4.00 |
Valuation & Earnings
This table compares Nuwellis and Nihon Kohden”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuwellis | $8.74 million | 0.42 | -$11.16 million | ($107.91) | -0.02 |
| Nihon Kohden | $1.48 billion | 1.33 | $93.05 million | $0.51 | 22.65 |
Nihon Kohden has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Nuwellis has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Nihon Kohden has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.
Institutional and Insider Ownership
3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 0.1% of Nihon Kohden shares are owned by institutional investors. 20.1% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Nuwellis and Nihon Kohden’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuwellis | -202.83% | -1,367.63% | -202.97% |
| Nihon Kohden | 5.32% | 7.25% | 5.12% |
Summary
Nihon Kohden beats Nuwellis on 11 of the 14 factors compared between the two stocks.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
About Nihon Kohden
Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
